histone h3.3-k27m neoantigen vaccine therapy
Vaccineexperimental
Clinical trial activity
1 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Mar 8, 2021 (NCT04749641)
Timeline
2020s
- Jan 1, 2021
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Tumor antigensImmunity, active
immunity, active - tumor antigens
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04749641 | Phase 1 | Mar 8, 2021 | Beijing Tiantan Hospital, Capital Medical University, TCRCure Biopharma Corp. |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Beijing Tiantan Hospital | Academic/Hospital | 1 | 1 | 1 | 2021 |
| Capital Medical University | Academic/Hospital | 1 | 0 | 1 | 2021 |
| TCRCure Biopharma Corp. | For profit | 1 | 0 | 1 | 2021 |
3 organizations
Page 1 / 1